Cellular based treatment modalities for unresectable hepatocellular carcinoma

doi:10.5306/wjco.v12.i5.290

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7674)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

537

WORD

184

HTML

4174

Figures (1-1)

293

Tables (1-3)

276

Sum=5464

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

302

Download

629

Sum=931

Publishing Process of This Article

Item

Count

Browse

415

Download

864

Sum=1279

May 24, 2021 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. May 24, 2021; 12(5): 290-308
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.290

Table 3 Ongoing clinical trials investigating cancer vaccines and oncolytic viruses in the treatment of hepatocellular carcinoma according to ClinicalTrials.gov

Product	Phase	Estimated completion	Study/identifier
OV telomelysin (OBP-301)	I	April 2021	NCT02293850
DC vaccine	II	April 2022	NCT04317248
DC vaccine + pneumococcal 13	I	May 2022	NCT03942328
OV M1-c6v1	I	October 2022	NCT04665362
DC vaccine	I	June 2023	NCT04147078
DSP-7888 PV + nivolumab or pembrolizumab	I/II	February 2024	NCT03311334
DNAJB1-PRKACA fusion kinase vaccine	I	March 2024	NCT04248569
TAEK-VAC-HerBy vaccine	I/II	December 2024	NCT04246671

DC: Dendritic cell; OV: Oncolytic virus; PV: Peptide vaccine.

Citation: Damiris K, Abbad H, Pyrsopoulos N. Cellular based treatment modalities for unresectable hepatocellular carcinoma. World J Clin Oncol 2021; 12(5): 290-308
URL: https://www.wjgnet.com/2218-4333/full/v12/i5/290.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i5.290